While Taysha Gene Therapies Inc has overperformed by 8.37%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TSHA rose by 241.67%, with highs and lows ranging from $3.89 to $0.50, whereas the simple moving average jumped by 20.00% in the last 200 days.
On April 09, 2024, Piper Sandler started tracking Taysha Gene Therapies Inc (NASDAQ: TSHA) recommending Overweight. A report published by Jefferies on February 01, 2023, Downgraded its rating to ‘Hold’ for TSHA. Morgan Stanley also Downgraded TSHA shares as ‘Equal-Weight’, setting a target price of $3 on the company’s shares in a report dated January 27, 2023. Goldman November 09, 2022d the rating to Neutral on November 09, 2022, and set its price target from $16 to $3. Robert W. Baird initiated its ‘Outperform’ rating for TSHA, as published in its report on March 09, 2022. Wells Fargo’s report from March 01, 2022 suggests a price prediction of $25 for TSHA shares, giving the stock a ‘Overweight’ rating. SMBC Nikko also rated the stock as ‘Outperform’.
Analysis of Taysha Gene Therapies Inc (TSHA)
Further, the quarter-over-quarter increase in sales is 44.04%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Taysha Gene Therapies Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -294.04% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 4.06, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and TSHA is recording an average volume of 2.78M. On a monthly basis, the volatility of the stock is set at 9.68%, whereas on a weekly basis, it is put at 9.55%, with a loss of -7.52% over the past seven days. Furthermore, long-term investors anticipate a median target price of $6.83, showing growth from the present price of $2.46, which can serve as yet another indication of whether TSHA is worth investing in or should be passed over.
How Do You Analyze Taysha Gene Therapies Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 31.23%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 62.26% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
TSHA shares are owned by institutional investors to the tune of 62.26% at present.
